6 days Ago By ABMN Staff
Franklin Resources Inc. bought a new position in IN8bio, Inc. ( NASDAQ:INAB – Free Report ) during the fourth quarter, according to its most recent Form 13F filing with the SEC.
The firm bought 5,696,202 shares of the company’s stock, valued at approximately $1,465,000. Franklin Resources Inc. owned approximately 7.
86% of IN8bio at the end of the most recent reporting period. Other institutional investors and hedge funds have also made changes to their positions in the company. Sigma Planning Corp lifted its position in IN8bio by 22.
3% during the fourth quarter. Sigma Planning Corp now owns 1,041,380 shares of the company’s stock worth $268,000 after buying an additional 190,100 shares in the last quarter. AIGH Capital Management LLC increased its stake in shares of IN8bio by 269.
7% in the 4th quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock worth $1,593,000 after acquiring an additional 4,517,227 shares during the last quarter. Finally, BIOS Capital Management LP purchased a new position in shares of IN8bio during the 4th quarter worth $2,212,000.
92.05% of the stock is currently owned by institutional investors and hedge funds. IN8bio Stock Up 4.
7 % INAB stock opened at $0.16 on Tuesday. IN8bio, Inc.
has a one year low of $0.13 and a one year high of $1.74.
The firm has a market cap of $12.94 million, a PE ratio of -0.21 and a beta of 0.
24. The firm’s 50 day moving average price is $0.23 and its 200-day moving average price is $0.
27. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.
84 and a current ratio of 1.84. Wall Street Analysts Forecast Growth Separately, HC Wainwright dropped their price objective on shares of IN8bio from $8.
00 to $6.00 and set a “buy” rating for the company in a report on Friday, March 14th. Read Our Latest Stock Report on INAB About IN8bio ( Free Report ) IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers.
Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. Further Reading Want to see what other hedge funds are holding INAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IN8bio, Inc.
( NASDAQ:INAB – Free Report ). Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter .
.
